Thought Leader

Mission of the MASLD Community

Dedicated to fostering collaboration, driving innovation, and improving outcomes for patients living with Metabolic Associated Steatotic Liver Disease.

Find a Thought Leader arrow arrow

Engage with MASLD/MASH Experts in Your Region

Connect with regional specialists for personalized guidance, professional training, and continuous support in MASLD/MASH.

Expert Insights

Benefit from expert-driven resources, including podcasts, publications, and practical tools designed for clinicians and patients.

Tailored Education for Your Community

Join your regional community network, where education is tailored to meet local needs. Collaborate with peers from local and regional communities, share knowledge, and drive impactful changes together.

Explore Our Events

Explore Our Events

CME EVENT

Breakthroughs in MASH Diagnosis & Management

January 13 @ 06:30 pm - 09:30 pm CST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with Bradley Freilich, MD, AGAF, Steven Fla..

CME EVENT

Breakthroughs in MASH Diagnosis & Management

January 14 @ 06:30 pm - 09:30 pm EST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with Satheesh Nair, MD, Ziad Younes, MD, &a..

CME EVENT

Breakthroughs in MASH Diagnosis & Management

January 14 @ 06:30 pm - 09:30 pm PST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with Sammy Saab, MD, MPH, Ke-Qin Hu, MD &am..

CME EVENT

Breakthroughs in MASH Diagnosis & Management

January 15 @ 06:30 pm - 09:30 pm PST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with Robert Wong, MD, M.S, Bilal Hameed, MD..

CME EVENT

Breakthroughs in MASH Diagnosis & Management

January 22 @ 06:30 pm - 09:30 pm PST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with Marina Roytman, MD, Paul Kwo, MD, &..

CME EVENT

Breakthroughs in MASH Diagnosis & Management

January 29 @ 06:30 pm - 09:30 pm MST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with Marcelo Kugelmas, MD, FAASLD, FACP, Ch..

CME EVENT

Breakthroughs in MASH Diagnosis & Management

February 05 @ 06:30 pm - 09:30 pm CST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with Mazen Noureddin, MD, MHSc.  &nbs..

CME EVENT

Breakthroughs in MASH Diagnosis & Management

February 10 @ 06:30 pm - 09:30 pm EST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with David Bernstein, MD, Robert S. Brown, ..

CME EVENT

Breakthroughs in MASH Diagnosis & Management

February 19 @ 06:30 pm - 09:30 pm EST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with John Binu, MD, MPH, Pierre Gholam, MD,..

CME EVENT

28th IU GI & Hepatology Update

February 27 @ 07:00 am - 03:25 pm EST

The IU Gastroenterology & Hepatology Update is an annual educational program designed for physicians, advanced practice providers (APPs), nurses, ..

CME EVENT

Breakthroughs in MASH Diagnosis & Management

March 04 @ 06:30 pm - 09:30 pm EST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with Niharika Samala, MD...

CME EVENT

Breakthroughs in MASH Diagnosis & Management

March 11 @ 06:30 pm - 09:30 pm CDT

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with Nancy Reau, MD, Sujit Janardhan, MD, P..

CME EVENT

Breakthroughs in MASH Diagnosis & Management

March 25 @ 06:30 pm - 09:30 pm EST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with Scott Minchenberg, MD, PhD, Michelle L..

CME EVENT

Breakthroughs in MASH Diagnosis & Management

March 26 @ 06:30 pm - 09:30 pm EST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with Kimberly Brown, MD, Robert Fontana, MD..

View All arrow

Featured MASLD/MASH Educators

play

Elizabeth Alqueza

PA-C

Elizabeth Alqueza, PA-C is a board certified Physician Associate at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. She graduated from the University of Florida in 2004 with a Master of Physician Assistant Studies degree and subsequently completed the AASLD NP/PA Clinical Hepatology Fellowship. Elizabeth has worked in a variety of inpatient and outpatient settings with a strong commitment to patient care. Currently working at BIDMC Liver Center, Elizabeth has 5 years of dedicated experience in Hepatology. Her practice focuses primarily on steatotic liver disease, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Elizabeth is an active member of Gastroenterology and Hepatology Advanced Practice Providers.

play

Michelle Barnett

PA-C, MPAS, DFAAPA

Michelle Barnett is a highly experienced physician assistant specializing in patient-focused and evidence-based hepatology at Peak Gastroenterology Associates in Colorado Springs, Colorado. The most rewarding part of her position includes educating patients and collaborating with other GI advanced practice providers to enhance care for the growing MASLD/MASH population. She is now a subinvestigtor for hepatology clinical trials with Peak in Colorado Springs. With over 30 years in the GI and liver communities, she has held leadership roles, including serving as President of the Colorado Academy of Physician Assistants (CAPA) and receiving CAPA's Physician Assistant of the Year award. She is a national speaker and has given lectures for the AAPA, GHAPP and AANP. A graduate of Wichita State University and the University of Nebraska, Michelle has been recognized with the DFAAPA distinction and honors such as the Crohn’s and Colitis Foundation's IBD internship and the International Foundation for Gastrointestinal Disorders Ally Award. Passionate about holistic care, she incorporates lifestyle strategies like nutrition, yoga, and meditation into her practice. Outside of work, Michelle enjoys hiking, travel, musical theater, and supporting her favorite Colorado sports teams.

play

Sherona Bau

NP

Sherona Bau graduated from University of California, Los Angeles in 2008, with Master of Science in Nursing dual program specialized in Acute Care Nurse Practitioner and Clinical Nurse Specialist. In 2010, she has joined UCLA Pfleger Liver Institute and Asian Liver Cancer Center working as an outpatient Nurse Practitioner specializing in liver diseases including viral hepatitis, hepatobiliary diseases, alcohol related liver diseases, Metabolic Dysfunction-Associated Steatotic Liver Disease/Steatohepatitis, autoimmune liver diseases, and hepatocellular carcinoma. Since 2016, she has been a guest lecturer at UCLA School of Nursing for Master Entry Clinical Nurse (MECN) and MSN Adult/Gero Acute Care program. She is also a preceptor for Adult/Gero Acute Care Program. She participated in Hepatitis C Screening in the Community Churches to promote awareness of hepatitis C and the importance of treatment of hepatitis C. She also participates in Patient Symposium at UCLA to give a lecture to update care of the liver transplant patients. She is also a faculty of Gastroenterology Hepatology Advanced Practice Provider (GHAPP) since 2018 and a speaker for both GHAPP National meeting and Regional GHAPP in Los Angeles. Since 2013, she has published total 14 research papers and case report including the most recent three are Recommendations for the Management of MASH by Advanced Practice Providers in the US, Clinicians and Patients Confront Practical Issues in Wilson Disease, and Overview of chronic Hepatitis B management.

play

Maribeth Capuno

DNP, RN, ANP-BC

Maribeth Capuno obtained her Master of Science in Nursing from Emory University in 1996. She was then certified as an Adult Nurse Practitioner. She worked as a Nurse Practitioner in Cardiology for over 20 years, specializing in Heart Failure. In 2019, she advanced her education by obtaining her Doctor of Nursing Practice from the University of Virginia. In 2021, she relocated to Richmond Virginia and took a position in the Hepatology department at the Richmond Veteran's Affairs Medical Center. In this position, her focus has been on patients with MASLD/MASH throughout the spectrum of their disease. She works with her patients to develop an individualized plan of care to assist them in controlling their metabolic conditions which are contributing to their liver disease. She also is a Sub-Investigator on multiple MASLD/MASH clinical trials.

play

Summer Collier

MSN, FNP-BC

Summer Collier is a nurse practitioner with advanced expertise in hepatology and a strong commitment to evidence-based, multidisciplinary care. At UC San Diego Health, she provides comprehensive management for patients with chronic liver disease, including viral hepatitis, autoimmune hepatitis, alcohol-associated liver disease, and metabolic dysfunction–associated steatotic liver disease (MASLD). Collier is actively engaged in clinical research and has participated in multidisciplinary studies on liver fibrosis, steatosis, and treatment protocols for hepatitis C and alcohol use disorder. Her scholarly work focuses on improving transitions of care for patients with cirrhosis and expanding access to pharmacologic treatments for patients with alcohol use disorder. A recognized leader in the field, Collier has presented at national conferences including The Liver Meeting (AASLD), Digestive Disease Week (DDW), and GHAPP, speaking on topics such as cirrhosis care, hepatology red flags, and advanced practice provider leadership. She previously served as Chair of the Advanced Practice Council at UC San Diego Health, driving initiatives that elevated APP visibility and impact within the organization. Before joining UC San Diego Health, she was a family nurse practitioner and HIV specialist with Family Health Centers of San Diego. She also has prior experience as a registered nurse. Collier completed a Master of Science in Nursing degree from University of San Diego and will complete the Doctor of Nursing Practice degree from University of California, Los Angeles in June 2025. She is certified by the American Nurses Credentialing Center.

play

Jessica Crimaldi

MSN, NP-C, CMSRN

Jessica Crimaldi, MSN, APRN,CNP, CMSRN was born and raised in the greater Cleveland area. She attended Cleveland State University for her BSN; during her time at CSU she had the opportunity to work at The Cleveland Clinic Foundation in a 3-year internship entitled the "Nursing Experiential Program." In this role she had the opportunity to learn many of the roles on a typical nursing unit while working 1 year as a Unit Secretary, 1 year as a Nurse Assistant and 1 year as a Nurse Intern. She started her nursing career on an inpatient Internal Medicine and Telemetry Teaching Unit where she worked as an RN while completing her MSN at the University of Akron. Since graduation in 2015 she has worked as a Nurse Practitioner in the Department of Gastroenterology, Hepatology and Nutrition seeing inpatients with gastrointestinal and liver disorders at The Cleveland Clinic Foundation. In addition, to her clinical role, she is also the Manager for over 50 Gastroenterology, Hepatology and Nutrition APPs. She is the Co-Director for the nation's first Inflammatory Bowel Disease APP Fellowship which is in its third year. She has presented nationally and published in The Journal for Nurse Practitioners (JNP). She is Faculty for Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) National Organization and Milestone APP. When she is not busy with work Jessica is a wife, parent to 2 young children and dog mom. She is a foster parent and passionate about improving the foster care system. She enjoys being outdoors, hiking and spending time with family and friends.

play

Jeremy Davis

ACNP-BC

Jeremy Davis ACNP is a board-certified acute care nurse practitioner who has been practicing in the focus of hepatology at GastroIntestinal Specialists A.M.C. since 2012. Jeremy’s areas of interest include MASLD, MASH, Hepatitis B, Hepatitis C, cholestatic liver disease, and autoimmune liver disease. Jeremy has been an active faculty ambassador of Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) since 2019 and is a lecturer at both regional and national conferences. Jeremy is also an Associate member of the American Association for the Study of Liver Diseases (AASLD) since 2014. Jeremy received his Bachelor of Science degree and Master of Science Degree in Nursing from Northwestern State University in Natchitoches, Louisiana. Jeremy’s hobbies include spending time with his family, cooking and traveling.

play

Sarah Dawkins

FNP-C, MSN, RN

Sarah Dawkins, FNP-C, is a family nurse practitioner specializing in general and transplant hepatology at Duke University Medical Center, where she has practiced since 2017. She holds a BS in Biology and a BA in Romance Languages from the University of North Carolina at Chapel Hill. Sarah completed the Accelerated Bachelor of Science in Nursing (ABSN) program at Duke University and worked in the Neuroscience ICU at Duke while earning her Master of Science in Nursing (MSN). She became a certified family nurse practitioner in 2015 and initially worked in a private gastroenterology practice before joining Duke Gastroenterology. Her clinical interests include autoimmune liver disease, transplant hepatology and metabolic dysfunction-associated steatotic liver disease (MASLD). Sarah currently serves as the Advanced Practice Provider (APP) Team Lead for the GI Division at Duke. Outside of work, she enjoys traveling, trying new restaurants, attending fitness classes, cheering on the UNC Tar Heels, and spending time with her three young children and their orange cat, Zeus.

play

Anthony Derencius

MPAS, PA-C

Anthony Derencius, PA-C is a former U.S. Army medic and a 2010 honor graduate of the military’s Interservice Physician Assistant Program. During his 11 years in the Army, he provided care to patients and soldiers around the world, including deployments to Afghanistan and Iraq. After leaving the Army, PA-C Derencius focused his clinical career in the gastroenterology and hepatology field. He has worked in private practice GI in Hawaii and in both general and transplant hepatology in San Antonio, gaining extensive outpatient and inpatient experience. In 2024, he joined Pinnacle Clinical Research, bringing a wealth of clinical expertise to his role as an investigator in many clinical trials for MASLD and other liver diseases. In 2018, he completed a one-year American Association for the Study of Liver Disease (AASLD) Foundation NP/PA Clinical Hepatology Fellowship. He is also an active member of several medical societies, including the American College of Gastroenterology (ACG) and the AASLD.

Stacie Egan

DNP, FNP-C

Stacie Egan, DNP, FNP-C, is a Family Nurse Practitioner specializing in gastroenterology, practicing with the Ogden Clinic in Utah. Born and raised in the Ogden area, she completed her Bachelor of Science in Nursing at Weber State University, graduating summa cum laude. She went on to earn her Master of Science in Nursing from the University of Cincinnati, and most recently her Doctor of Nursing Practice degree, which she obtained in 2022. Stacie joined Ogden Clinic in 2017 and works primarily through the Layton Specialty location, where she focuses on digestive health, disease prevention, and helping patients improve quality of life through clinical care and education. Her passion for gastroenterology stems from her strong belief in the impact of preventative health and the importance of gut health in overall wellness. Beyond her clinical work, Stacie values a patient-centered approach—listening to patients, addressing their concerns, and applying her knowledge to support them in achieving better health outcomes. She resides locally, is married, and in her free time enjoys Utah’s outdoor lifestyle, including trail running, enjoying natural areas like Snowbasin, and participating in the Ogden Marathon.

play

Melissa Franco

PA-C, MMS

Melissa Franco is a Physician Associate at the University of Miami- specializing in the management of patients with liver diseases, ranging from acute hepatitis to complex chronic conditions such as cirrhosis and liver cancer. With a strong focus on MASH, autoimmune hepatitis, PBC, viral hepatitides, and cirrhosis- Melissa is dedicated to delivering compassionate, comprehensive care tailored to each patient's unique needs. She is deeply committed to patient education, and strives to empower individuals to take an active role in their health journey, fostering collaboration, and confidence at every stage of care.

play

Jennifer Geremia

PA-C

Jennifer Geremia, PA-C, is a practicing Physician Assistant in outpatient Gastroenterology at Brigham and Women's Hospital in Boston. With GI experience for 15 years including community GI care in RI and currently tertiary care. In addition to clinical practice she enjoys educating both her peers and future PAs. Jennifer currently teaches at UNE, MCPHS and MGH PA programs. She is also on the Education committee and faculty for GHAPP and is actively working on the AGA APP task force as well as an APP contributor to ASGE .

play

HoChong Gilles

DNP, FNP-BC, AF-AASLD

HoChong Gilles earned dual Bachelor of Science degrees in Biology and Nursing, followed by a Master of Science in Nursing from Virginia Commonwealth University. In 2018, she completed her Doctorate in Nursing Practice at the University of Virginia. With over 25 years of experience as a Nurse Practitioner specializing in hepatology, Dr. Gilles currently serves as the Clinical Program Director for the Gastroenterology and Hepatology Division and Assistant Director of GI Research in Richmond, Virginia. Her clinical and research interests encompass metabolic dysfunction associated steatotic liver disease (MASLD/MASH), portal hypertension, liver transplantation, and hepatocellular carcinoma. An active member of the liver disease community, she is proud to hold the designation of Associate Fellow with the American Association for the Study of Liver Disease (AASLD).

play

Elizabeth Goacher

PA-C

Elizabeth Goacher is a Physician Assistant with Duke University Medical Center, Department of Medicine, Gastroenterology Division, Duke Liver Center, April 2001 to the present. Her pronouns are she/her. She is currently engaged in full time clinical practice in Hepatology. Her clinical work encompasses the full spectrum of liver disease patient population, from early stage disease to end of life, with a particular interest in portal hypertension. She served as Team Lead for the Duke Division of Gastroenterology Advanced Practice group of 25 Advanced Practice Providers 2014-2023. She is also lecturer and preceptor at Duke University School of Medicine Physician Assistant Program. Elizabeth graduated from the Duke University School of Medicine Physician Assistant Program in 1998 after earning her Bachelor of Arts from University of North Carolina at Chapel Hill in 1991. She is past Chair of the Hepatology Associates Committee of the American Association for the Study of Liver Diseases and was a member of the inaugural class of Associate Fellows of AASLD in 2020. When she is not at work, she maintains a health boundary from technology (aka EPIC) and spends as much time outdoors as possible. When asked to design and implement her dream job, she would own and operate a cocktail and tapas venue while instructing fitness classes on a large piece of lakeside property in North Carolina alongside her canine rescue, foster and retraining agency.

play

Ellie Gonyeau

NP

Ellie Gonyeau is a board-certified Nurse Practitioner specializing in gastroenterology at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. She earned her Nurse Practitioner degree from Simmons University and has been practicing since 2020. Ellie is affiliated with Cape Cod Hospital and Beth Israel Deaconess Medical Center, providing comprehensive care to patients with various gastrointestinal conditions. She is committed to delivering patient-centered care and building long-term, trusting relationships with her patients.

play

Tina Gregg

NP-C

Tina Marie Gregg, NP-C, is a board-certified nurse practitioner specializing in gastroenterology with a particular focus on liver disease. She serves as The Liver Clinic Specialist at GI Associates & Endoscopy Center in Flowood, Mississippi, where she provides comprehensive care for patients with conditions such as cirrhosis, fatty liver disease, hepatitis, and other chronic liver disorders. Tina earned her Master of Science in Nursing degree from University of Mississippi Medical Center and has been certified by the American Academy of Nurse Practitioners since 2007. At GI Associates, she is actively involved in clinical care, coordinating diagnostic evaluations, treatment plans, and long-term disease management. She also serves as a Sub-investigator within the Research Department. Known for her compassionate and thorough approach, Tina is dedicated to helping patients understand their conditions and treatment options while ensuring close follow-up and ongoing support.

play

Janet Gripshover

DNP, FNP-BC, MBA

Janet Gripshover, DNP, FNP-BC, MBA, AF-AASLD, is a highly experienced Family Nurse Practitioner and Nurse Manager for Cedars-Sinai’s Liver Transplant Program in Los Angeles. With over 15 years of clinical and leadership expertise in hepatology, Dr. Gripshover is recognized for her commitment to advancing the role of Advanced Practice Providers (APPs) in liver care. She has led numerous initiatives to foster APP education and collaboration, including founding the APP HCV Consortium in Baltimore, MD, and creating the GI APP Grand Rounds series at Geisinger Wyoming Valley in Wilkes-Barre, PA. In addition to speaking at national conferences, Dr. Gripshover has developed and delivered a wide range of educational and professional development seminars for non-physician providers across the country. An advocate for patient-centered innovation, she also founded and moderated the first hospital-sponsored Facebook support group for liver transplant recipients — a project that earned her the New Media Award for Healthcare from the Baltimore Business Journal and national recognition. Dr. Gripshover is an active member of the American Association for the Study of Liver Diseases (AASLD), where she has served on the Hepatology Associates Committee and the Women’s Initiatives Committee, helping launch the AASLD Women’s Leadership Program. She currently serves as Vice Chair of AASLD’s Hepatology Associates Special Interest Group and is also a member of the Hepatology Associates Committee for the American College of Gastroenterology (ACG).

play

Christina Hanson

FNP-C

Christina Hanson is a nurse practitioner in Gastroenterology and Hepatology at South Denver GI, with nearly 20 years of clinical practice. She is a course director and board of trustee for GHAPP. An active researcher with extensive leadership and teaching experience, she is a champion of evidence-based practice, data-driven care delivery, interdisciplinary collaboration, and quality patient care. Christina is committed to amplifying professional development, growth, and contributions of advanced practice.

Anna Marie Hefner

PhD, RN, CPNP, FAASLD

Anna Marie Hefner PhD, RN, CPNP, FAASLD is a board-certified Pediatric Nurse Practitioner, and expert nurse in the field of Hepatology, specializing in fatty liver disease and non-alcoholic steatohepatitis. Anna Marie is an Associate Professor at Azusa Pacific University, School of Nursing, where she teaches undergraduate and graduate nursing students. Anna received her Masters of Science in Nursing from California State University in Long Beach, and her Masters of Arts, Education, and Special Education at Azusa Pacific University. Anna Marie completed her Doctorate in Nursing at the University of San Diego, with an emphasis in nutritional status of the patient with end-stage liver disease. Anna Marie is the Director of the NASH-ville clinics at Southern California Liver Centers. Anna Marie has received three consecutive mid-level professional awards for her work on facilitating lifestyle changes to manage progressive fatty liver disease from the American Association for the Study of Liver Diseases. Anna Marie is a member of the National Association of Pediatric Nurse Practitioners and the American Academy of Nurse Practitioners.

play

Patrick Horne

NP

Patrick M. Horne, MSN, APRN-BC, FNP, AF-AASLD is the Assistant Director of Clinical Hepatology Research and Clinical Programs Coordinator at the University of Florida’s Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition. He holds bachelor's and master's degrees from the University of Florida College of Nursing. His research focuses on hepatology clinical trials, including viral hepatitis, MASH, autoimmune hepatitis, cholestatic liver disease, and HCC. He has published extensively in clinical hepatology and has presented at major conferences such as AASLD, AGA NP/PA, and GHAPP.

View All arrow arrow

MASLD/MASH Learning Center

Latest News & Blogs

Multifrequency MR elastography for grading inflammation in metabolic dysfunction-associated steatotic liver disease: a pilot study

December 2025

CONCLUSION: The multifrequency dispersion coefficient α was associated with histologic inflammation and should be further evaluated with external validation as a possible clinical marker in MASLD.

Read More arrow

Diagnostic performance of non-invasive markers for distinguishing MASLD/MASH: insights from meta-analysis and real-world data

December 2025

CONCLUSION: This meta-analysis and cross-sectional validation confirm that non-invasive biomarkers, such as FLI, FIB-4, and NFS, demonstrate significant diagnostic accuracy for MASLD and MASH. The findings highlight the value of these tools for widespread, cost-effective screening in at-risk populations.

Read More arrow

Targeting RNA Polymerase I Inhibits Ribosome Biogenesis to Block Liver Fibrosis Progression

December 2025

CONCLUSIONS: Pol I-regulated ribosome biogenesis is significantly increased during HSCs activation and liver fibrosis progression. Pol I may serve as a potential target for the diagnosis and treatment of liver fibrosis.

Read More arrow

The SERCA-PLN-DWORF axis in cardiometabolic disease: mechanisms and therapeutic perspectives

December 2025

Intracellular calcium (Ca^(2+)) homeostasis is a central determinant of cardiometabolic physiology, integrating excitation-contraction coupling, metabolic signaling, and stress adaptation across multiple organs. The sarco/endoplasmic reticulum Ca^(2+)-ATPase (SERCA), regulated by the micropeptides phospholamban (PLN) and dwarf open reading frame (DWORF), governs ER/SR Ca^(2+) reuptake and thereby shapes Ca^(2+)-dependent signaling dynamics. Dysregulation of the SERCA-PLN-DWORF axis is...

Read More arrow

Metabolic surgery in metabolic dysfunction-associated steatohepatitis: emerging evidence and clinical promise

December 2025

No abstract

Read More arrow

Hepatic CD4 T Cells Predict Hepatocellular Carcinoma Risk on Metabolic Dysfunction-Associated Steatohepatitis Patients

December 2025

CONCLUSIONS: Increase in liver CD4+ T cell infiltration characterizes MASH-to-HCC progression. These immune signatures combined with clinical parameters demonstrate remarkable predictive value for identifying high-risk MASH patients.

Read More arrow

Cichoriin suppresses hepatic lipid accumulation and fibrosis in mice metabolic dysfunction associated steatohepatitis via the AMPK pathway

December 2025

Previous studies highlight the critical role of AMP-activated protein kinase (AMPK) in hepatic lipid metabolism, yet natural activators for metabolic dysfunction-associated steatohepatitis (MASH) remain underexplored. This study investigated whether cichoriin from Cichorium intybus mitigates MASH fibrosis. C57BL/6J mice fed a Gubra-Amylin NASH diet for 20 weeks received cichoriin (100 or 200 mg/kg/day, oral gavage) for 6 weeks. Primary murine hepatocytes and hepatic stellate cells (HSCs) were...

Read More arrow

ZIF-8 gated dual miRNA-sensing nanoplatform for enzyme-free amplification and precision diagnosis of metabolic dysfunction-associated steatohepatitis

December 2025

Ultrasensitive and reliable imaging of miRNAs in living cells facilitates advanced understanding of diseases and pathological progression. However, synchronous detection of multicomponent miRNAs remains challenging due to obstacles in the efficient co-delivery of probes and their inherently low abundance. Herein, we present a versatile Hairpins@ZIF-8 nanoplatform by integrating ZIF-8 with three hairpins for dual miRNA sensing. This system enables synchronous cellular transfection of nucleic acid...

Read More arrow

Pharmacotherapy for obesity management

December 2025

RECOMMENDATIONS 1. Pharmacotherapy for obesity management can be used for individuals with a BMI ≥30 kg/m2, or ≥27 kg/m2 with adiposity-related complications, in conjunction with medical nutrition therapy, physical activity and psychological interventions (semaglutide 2.4 mg weekly [Level 1a, Grade A] liraglutide 3.0 mg daily [Level 2a, grade B], naltrexone/bupropion 16 mg/180 mg twice a day [BID] [Level 2a, Grade B], orlistat 120 mg three times a day [TID] [Level 2a, Grade B]). 2....

Read More arrow

Current Immunotherapy Strategies and Emerging Biomarkers for the Treatment of Hepatocellular Carcinoma

December 2025

CONCLUSIONS: We review current research and its integration into clinical practice, advancing HCC therapy toward personalized, patient-centered care.

Read More arrow

Endoscopic sleeve gastrectomy vs traditional bariatric surgery: A paradigm shift in managing metabolic dysfunction-associated steatohepatitis and cirrhosis?

December 2025

Metabolic dysfunction-associated steatohepatitis (MASH) has become a leading indication for liver transplantation. Bariatric surgery is a proven intervention for weight loss and metabolic improvement in MASH but concerns over surgical risk in patients with advanced liver disease has expanded interest in endoscopic sleeve gastroplasty (ESG) as a less invasive alternative. This review examine the efficacy, safety, and metabolic impact of ESG vs traditional bariatric surgery (Roux-en-Y gastric...

Read More arrow

Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends

December 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD), recognized as the most prevalent liver disease worldwide and a leading cause of liver transplantation, is closely associated with type 2 diabetes, cardiovascular disease, and metabolic dysfunction. Its multifactorial pathogenesis involves insulin resistance, lipotoxicity, gut dysbiosis, and dysregulated signaling involving multiple receptors and pathways, culminating in hepatic steatosis, inflammation, fibrosis, and, ultimately,...

Read More arrow

Adiposity and Metabolic Indices in the Diagnosis and Histological Stage Association of Metabolic Dysfunction-Associated Steatotic Liver Disease

December 2025

Background: Metabolic dysfunction-associated steatotic liver disease (MALSD) is defined as the excessive accumulation of triglycerides in the liver in the presence of at least one cardiometabolic risk factor and liver biopsy remains the diagnostic gold standard. This study aimed to evaluate the diagnostic performance of adiposity and metabolism related indices for the non-invasive detection of MASLD and the metabolic dysfunction-associated steatohepatitis (MASH). Methods: A cross-sectional study...

Read More arrow

Association Between Left Ventricular Global Longitudinal Strain and Hepatic Inflammation and Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease

December 2025

Background/Objectives: Cardiovascular disease is the leading cause of mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), which includes simple steatosis (metabolic dysfunction-associated steatotic liver, MASL), metabolic dysfunction-associated steatohepatitis (MASH), and fibrosis. This study aimed to evaluate the association between left ventricular (LV) systolic function, measured by global longitudinal strain (GLS), and liver inflammation and fibrosis...

Read More arrow

Pruritus and health-related quality of life in chronic liver disease: a longitudinal, survey-based cohort study

December 2025

CONCLUSION: Our study highlights the burden of pruritus experienced by participants across CLDs, highlighting a need to improve symptom recognition and treatments focused on improving HRQoL.

Read More arrow

BRUCE liver-KO enhances MASLD/MASH development in the steatotic PTEN-KO background by impairing mitochondrial metabolism and activating STAT3

December 2025

The IAP BRUCE (Birc6) plays multifaceted roles in apoptosis inhibition, DNA repair, and autophagy. Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), affect up to 30% of the global population, yet their pathogenic mechanisms remain poorly understood. Given BRUCE's high expression in healthy livers and its downregulation in MASLD/MASH, we investigated its functional role using liver-specific BRUCE-KO...

Read More arrow

Screening and management of metabolic dysfunction-associated steatotic liver disease (MASLD)

December 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is an increasingly prevalent condition that poses significant public health challenges. Affecting nearly 30% of the global population, MASLD is intricately linked to metabolic syndrome, insulin resistance, and cardiovascular disease. Primary care providers, including physician associates (PAs), play a critical role in early detection and management. This article provides...

Read More arrow

Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis

December 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease, affecting more than 30% of adults and 7%-14% of youths globally. MASLD and its advanced form of metabolic dysfunction-associated steatohepatitis (MASH) can progress to liver cirrhosis and hepatocellular carcinoma. Despite its growing burden, effective therapies for MASLD and MASH remain limited. Accumulating evidence indicates that short-chain fatty acids (SCFAs) modulate the activation of...

Read More arrow

Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis

December 2025

BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH), a progressive subtype of steatotic liver disease, imposes a substantial global health burden due to its association with obesity and metabolic syndrome. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate therapeutic potential through pleiotropic mechanisms, including appetite regulation, metabolic enhancement, and anti-inflammatory activity. However, clinical evidence remains limited by methodological...

Read More arrow

Analysis of risk factors and correlation between the degree of hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatohepatitis

December 2025

CONCLUSIONS: There is a positive correlation between liver steatosis and fibrosis. Establishing non-invasive prediction model for liver fibrosis has a good predictive value for liver fibrosis in MASH.

Read More arrow
View All arrow arrow